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STUDY PROTOCOL
Allergen immunotherapy for insect 
venom allergy: protocol for a systematic review
Sangeeta Dhami1* , Ulugbek Nurmatov2, Eva‑Maria Varga3, Gunter Sturm4, Antonella Muraro5, 
Cezmi A. Akdis6,7, Darío Antolín‑Amérigo8, M. Beatrice Bilò9, Danijela Bokanovic10, Moises A. Calderon11,12, 
Ewa Cichocka‑Jarosz13, Joanna N. G. Oude Elberink14, Radoslaw Gawlik15, Thilo Jakob16, Mitja Kosnik17, 
Joanna Lange18, Ervin Mingomataj19,20, Dimitris I. Mitsias21, Holger Mosbech22, Oliver Pfaar23, 
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and Aziz Sheikh31
Abstract 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the 
EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Insect Venom Allergy. We seek to critically 
assess the effectiveness, cost‑effectiveness and safety of AIT in the management of insect venom allergy.
Methods: We will undertake a systematic review, which will involve searching international biomedical databases 
for published, in progress and unpublished evidence. Studies will be independently screened against pre‑defined 
eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and 
appropriate, quantitatively synthesised.
Discussion: The findings from this review will be used to inform the development of recomendations for EAACI’s 
Guidelines on AIT.
Keywords: Allergy, Insect sting, Hymenoptera venom allergy, Insect venom allergy, Allergen immunotherapy, 
Systemic sting reaction
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hymenoptera venom allergy is a potentially life-threat-
ening allergic reaction following one or more stings to 
bees, wasps, polistes, hornets or fire ants. The risk of ana-
phylaxis to hymenoptera stings is greater in adults when 
compared to children due to increased sting exposure, 
co-morbidities and concomitant medications in this age 
group. Systemic reactions have been reported in up to 
3 % of adults and 0.34 % of children [1, 2].
Symptoms range from large local reactions at the sting 
site to mild, moderate, and severe systemic reactions. 
Mild systemic reactions are usually generalized skin 
symptoms such as flush, urticaria and angioedema. Typi-
cally, dizziness, dyspnea, nausea are moderate symptoms 
while anaphylactic shock, asthma, loss of consciousness, 
or even cardiac or respiratory arrest all indicate a severe 
sting reaction. The fear of future reactions usually greatly 
impairs quality of life. Around a quarter of fatalities from 
anaphylaxis are triggered by venom allergy [3–5].
Patients are advised to carry an emergency kit contain-
ing H1-antihistamines, corticosteroids, and adrenaline 
(epinephrine) depending on their previous sting reac-
tion. The only treatment that can potentially prevent fur-
ther severe reactions is venom immunotherapy (VIT). 
This may be effective with long-term clinical benefit and 
improved quality of life [6, 7]. However, despite its life-
saving potential, VIT is still being under-prescribed and 
under-used in Europe [8].
The European Academy of Allergy and Clinical Immu-
nology (EAACI) is in the process of developing the 
EAACI Guidelines for AIT. This systematic review is 
one of five inter-linked evidence syntheses that are being 
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undertaken in order to provide a state-of-the-art synop-
sis of the current evidence base in relation to evaluating 
AIT for the treatment of insect venom allergy, allergic 
rhinoconjunctivitis, food allergy and allergic asthma, and 
allergy prevention. These will be used to inform the for-
mulation of key clinical recommendations for subsequent 
clinical guidelines. The focus of this review is on assess-
ing the effectiveness, safety and cost-effectiveness of VIT 
in the treatment of insect venom allergy.
Methods
Search strategy
A highly sensitive search strategy has been developed, 
and validated study design filters will be applied to 
retrieve all articles pertaining to the use of VIT for insect 
venom allergy from electronic bibliographic databases. 
We have conceptualized the search to incorporate the 
four elements below as shown in Fig. 1.
To retrieve systematic reviews, we will use the sys-
tematic review filter developed at McMaster University 
Health Information Research Unit (HIRU) (http://hiru.
mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strate-
gies.aspx#Reviews). To retrieve randomized controlled 
trials (RCTs), we will apply the Cochrane highly sensi-
tive search strategy for identifying RCTs in MEDLINE 
[9]. To retrieve non-randomized studies, i.e. controlled 
clinical trials (CCTs), controlled before-and-after (CBA) 
and interrupted time-series (ITS) studies, we will use the 
Cochrane Effective Practice and Organisation of Care 
(EPOC) filter Version 2.4, available on request from the 
EPOC Group [10, 11]. To retrieve case series, we will 
use the filter developed by librarians at Clinical Evi-
dence: http://clinicalevidence.bmj.com/x/set/static/ebm/
learn/665076.html.
We will search the following databases:
  • Cochrane Library including:
• Cochrane Database of Systematic Reviews (CDSR)
•  Database of Reviews of Effectiveness (DARE)
•  CENTRAL (Trials)
•  Methods Studies
•  Health Technology Assessments (HTA)
•  Economic Evaluations Database (EED)
  • MEDLINE (OVID)
  • Embase (OVID)
  • CINAHL (Ebscohost)
  • ISI Web of Science (Thomson Web of Knowledge)
  • TRIP Database (www.tripdatabase.com)
  • Clinicaltrials.gov (NIH web).
  • Clinicaltrialsregister.eu
  • Current controlled trials (www.controlled-trials.com)
  • Australian and New Zealand Clinical Trials Registry 
(http://www.anzctr.org.au).
The search strategy has been developed on OVID 
MEDLINE and then adapted for the other databases (see 
“Appendix”). In all cases, the databases will be searched 
from inception to October 31, 2015. Additional refer-
ences will be located through searching the references 
cited by the identified studies, and unpublished work and 
research in progress will be identified through discussion 
with experts in the field. We will invite experts who are 
active in the field from a range of disciplines and regions 
to add to the list of included studies by identifying addi-
tional published and unpublished papers they are aware 
of and research in progress. There will be no language 
restrictions employed; where possible, all relevant litera-
ture will be translated into English.
Fig. 1 Conceptualization of systematic review of allergen immunotherapy for insect venom allergy
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Inclusion criteria
Patient characteristics
We are interested in identifying studies conducted on 
patients of any age with a physician confirmed diagnosis 
of systemic sting reaction to a venom sting from fire ants, 
bees and bumble bees, and paper wasps and wasps.
Interventions of interest
This review is focused on VIT using different products 
(purified and non-purified aqueous or depot) and dif-
ferent treatment protocols (conventional, cluster, rush 
and ultra-rush) adminsitered through the SCIT or SLIT 
routes.
Comparators
We are interested in studies comparing VIT with placebo 
or no treatment (i.e. a natural course of the disease).
Study designs
Systematic reviews of RCTs, and RCTs, will be used 
to investigate effectiveness; health economic analysis 
will be used to assess cost-effectiveness; and systematic 
reviews, and RCTs and case series with a minimum of 
300 patients will be used to assess safety. We will appraise 
the evidence by looking at higher levels of evidence such 
as systematic reviews and/or meta-analyses of RCTs, 
together with individual RCTs. However, given the likeli-
hood that we will find only a limited number of RCTs, we 
will also search for and include quasi-RCTs—[i.e. non-
randomized CCTs, controlled before and after (CBA) 
studies and interrupted time series (ITS) analyses]. Given 
the high inherent risk of bias in making inferences from 
quasi-RCTs, clinical recommendations will be based on 
the findings from randomized controlled trials and the 
quasi-randomized controlled trials will only be used to 
guide suggestions on which areas need to be prioritized 
in future research [12].
Outcomes
Primary
  • Efficacy assessed by tolerated sting challenge or field 
sting both short-term and long-term, where long-
term is defined as sustained clinical efficacy after dis-
continuation of treatment (VIT).
Secondary
  • Assessment of disease specific quality of life;
  • Safety as assessed by local and systemic reactions in 
accordance with the World Allergy Organization’s 
grading system of side-effects [13, 14];
  • Health economic analysis from the perspective of the 
health system/payer.
Exclusion criteria
  • Reviews, discussion papers, non-research letters and 
editorials;
  • Animal studies;
  • Quantitative studies not employing systematic review 
or RCT or quasi-RCT designs;
  • Qualitative studies;
  • Case series (<300 patients).
Study selection
All references will be uploaded into the systematic 
review software Distiller and undergo initial de-duplica-
tion. Study titles will be independently checked by two 
reviewers according to the above selection criteria and 
categorized as: included, not included or unsure. For 
those papers in the unsure category, we will retrieve the 
abstract and re-categorize as above. Any discrepancies 
will be resolved through discussion and, if necessary, a 
third reviewer will be consulted. Full text copies of poten-
tially relevant studies will be obtained and their eligibility 
for inclusion independently assessed. Studies that do not 
fulfil all of the inclusion criteria will be excluded.
Quality assessment strategy
Quality assessments will independently be carried out on 
each study by two reviewers using the relevant version of 
the Critical Appraisal Skills Programme (CASP) quality 
assessment tool for systematic reviews and health eco-
nomic evaluations [15]. We will assess the risk of bias of 
experimental studies using the criteria suggested by the 
Cochrane EPOC Group [16]. RCTs, CCTs and CBAs will 
be assessed for generation of allocation sequence, con-
cealment of allocation, baseline outcome measurements, 
baseline characteristics, incomplete outcome data, blind-
ing of outcome assessor, protection against contamina-
tion, selective outcome reporting and other risks of bias 
using the Cochrane risk of bias tool. For ITS designs, 
we will also assess the independence of the interven-
tion from secular trends, the pre-specified shape of the 
intervention and if the intervention may have had an 
impact on data collection. These methodological assess-
ments will draw on the principles incorporated into the 
Cochrane EPOC guidelines for assessing intervention 
studies [17]. Similarly, we will use the quality assessment 
form produced by the National Institute for Health and 
Clinical Excellence (NICE) to critically appraise case 
series [18]. Any discrepancies will be resolved by discus-
sion or, if agreement could not be reached, by arbitration 
by a third reviewer.
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Analysis, data synthesis and reporting
Data will be independently extracted onto a custom-
ized data extraction sheet in Distiller by two reviewers, 
and any discrepancies will be resolved by discussion or, 
if agreement cannot be reached, by arbitration by a third 
reviewer.
A descriptive summary with data tables will be pro-
duced to summarize the literature. If clinically and statis-
tically appropriate, meta-analysis using either fixed-effect 
or random-effects modeling will be undertaken [9]. A 
narrative synthesis of the data will also be undertaken.
Sensitivity and subgroup analyses, and assessment 
for publication bias
Sensitivity analyses will be undertaken by comparing the 
summary estimates obtained by excluding studies judged 
to be at high risk of bias.
Subgroup analyses will be undertaken to compare:
  • Children (5–11  years) versus adolescents (12–
17 years) versus adults (≥18 years);
  • Conventional versus cluster versus rush versus ultra-
rush protocols in SCIT;
  • Conventional in SLIT versus SCIT;
  • 3 versus 5 years of treatment;
  • Different allergen doses (50 vs. 100 vs. 200  µg of 
maintenance VIT);
  • Bee versus wasp venom;
  • Comparing outcomes between those with and with-
out co-existent mast cell disease [19].
Where possible, publication bias will be assessed 
through the creation of funnel plots, and tested by Egg-
er’s regression test and Begg’s rank correlation test [20, 
21].
Registration and reporting
This review will be registered with the International Pro-
spective Register of Systematic Reviews (PROSPERO): 
http://www.crd.york.ac.uk/prospero/. The Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist will be used to guide the 
reporting of the systematic review: http://www.prisma-
statement.org/.
Discussion
This review will involve systematically identifying, cri-
tiquing and synthesizing the evidence on the efficacy/
effectiveness, cost-effectiveness and safety of VIT for the 
management of venom allergy. The findings from this 
review will be used to inform the development of recom-
mendations for EAACI’s Guidelines on AIT. We antici-
pate that this review will be reported in 2016.
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Appendix: Search strategy
Search strategy 1 (MEDLINE, EMBASE)
 1. insect sting.mp. or exp insect sting/
 2. insect bite.mp. or exp insect bite/
 3. insect allergy.mp. or exp insect allergy/
 4. exp immediate type hypersensitivity/or exp delayed 
hypersensitivity/or exp hypersensitivity/or hyper-
sensitivity.mp.
 5. hypersensitivity reaction.mp. or allergic reaction/
 6. anaphyla$.mp.
 7. systemic anaphylaxis/or exp anaphylaxis/or anaphy-
laxis.mp.
 8. systemic reaction.mp.
 9. shock.mp. or anaphylactic shock/or exp traumatic 
shock/or exp shock/
 10. hives.mp. or exp urticaria/
 11. laryngeal obstruction.mp. or exp larynx stenosis/
 12. angioedema.mp.
 13. airway obstruction.mp. or exp airway obstruction/
 14. exp Hymenoptera venom/or exp Hymenoptera/or 
hymenoptera.mp.
 15. exp bee venom/or exp bee/or bee.mp.
 16. honey bee.mp. or exp honeybee/
 17. wasp*.mp. or wasp venom.mp. or exp wasp venom/
 18. exp ant sting/or ant.mp. or exp ant/or exp ant 
venom/
 19. sawfl*.mp.
 20. (apis mellifera or vespid or vespula or white hor-
net or yellow jacket or yellow hornet or polistes or 
arthropod venom or solenopsis invicta or myrmecia 
pilosula).mp.
 21. or/1–20
 22. immunotherapy.mp. or exp subcutaneous immuno-
therapy/or exp immunotherapy/
 23. venom immunotherapy.mp.
 24. allergen immunotherapy.mp.
 25. specific immunotherapy for hymenoptera venom.mp.
 26. immunomodulation.mp. or exp immunomodulation/
 27. immunologic response.mp. or exp immune 
response/
 28. subcutaneous immunotherapy.mp. or exp subcuta-
neous immunotherapy/or sublingual immunother-
apy.mp. or exp sublingual immunotherapy/
 29. (intradermal immunotherapy or intralymphatic 
immunotherapy).mp.
 30. specific immunotherapy.mp.
 31. exp systematic desensitization/or exp desensitiza-
tion/or desensitization.mp.
 32. hyposensitization.mp.
 33. or/22–32
 34. intervention stud*.mp. or exp intervention study/
 35. experimental stud*.mp.
 36. exp “clinical trial (topic)”/or exp “controlled clini-
cal trial (topic)”/or exp “randomized controlled trial 
(topic)”/or trial.mp. or exp controlled clinical trial/
 37. (randomi?ed controlled trial or non-randomi?ed trial 
or quasi-randomi?ed trial).mp.
 38. placebos.mp. or exp placebo/
 39. random allocation.mp. or exp randomization/
 40. double blind procedure/
 41. (double-blind or double blind).mp.
 42. (single-blind or single blind).mp.
 43. (triple-blind or triple blind).mp.
 44. random*.mp.
 45. interrupted time series.mp.
 46. (controlled before and after stud* or controlled 
before-and-after stud*).mp.
 47. controlled before after design.mp.
 48. search:.tw.
 49. review.pt.
 50. systematic review.tw.
 51. meta analysis.mp,pt.
 52. case series.mp.
 53. cost effective:.mp.
 54. cost utility:.mp.
 55. exp health care costs/
 56. (costs and costs analysis).mp.
 57. economic evaluation*.mp.
 58. ((cost effective* adj1 analys*) or cost minimi?ation 
analys* or cost benefit analys* or cost utility analys* 
or cost consequence analys* or finances).mp.
 59. or/34–58
 60. 21 and 33 and 59
Search strategy 2: (Cochrane library, HTA, EED, CINAHL, ISI 
Web of Science, TRIP)
(Insect sting or insect bite or bee sting or bumble bee 
sting or wasp sting or paper wasp sting or ant sting or 
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fire ant sting or insect allergy or venom allergy or insect 
venom allergy or bee sting allergy or wasp sting allergy 
or fire ant allergy or hypersensitivity or immediate type 
hypersensitivity or delayed hypersensitivity or allergic 
reaction or severe allergic reaction or anaphylaxis or ana-
phylactic shock)
AND
(Immunologic, desensiti* or immunotherapy or venom 
immunotherapy or specific immunotherapy for hyme-
noptera venom or subcutaneous immunotherapy or 
sublingual immunotherapy or intradermal immuno-
therapy or intralymphatic immunotherapy or specific 
immunotherapy)
AND
(Intervention stud* or experimental stud* or trial or 
clinical trial* or controlled clinical trial or randomi* con-
trolled trial or quasi-ranomi* controlled trial or random 
allocation or single blind method or double blind method 
or triple blind method or random* or interrupted time 
series or controlled before and after stud* or system-
atic review or meta-analysis or case series or economic 
evaluation* or cost effective* analys* or cost minimi?ation 
analys* or cost benefit analys* or cost utility analys* or 
cost consequence analys* or finances).
Received: 25 November 2015   Accepted: 11 January 2016
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